Drug Trial Radar · NCT03207438
Melancholic Depression and Insomnia as Predictors of Response to Quetiapine in Patients With Major Depression
Last checked: Nov 20, 2026Latest source record: Dec 4, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,790
Actual
Start
Apr 2006
Primary completion
Jul 2007
Study completion Oct 2019
Sponsor
- Lead sponsor
- University of SaskatchewanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- AstraZeneca
- First posted
- Jul 2, 2017
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In essence the researchers are hoping to test two separate hypotheses (described below in the form of research questions). Therefore, the proposed analysis has been outlined according to each hypothesis. Hypothesis 1: Is low-dose quetiapine (50 mg/day) more effective for patients with depression who have insomnia at treatment baseline? (Stated differently: is low-dose quetiapine 50 mg/day effective as monotherapy for patients with depression regardless of whether or not they have insomnia at baseline?). Hypothesis 2: Is high-dose quetiapine (150 - 300 mg/day) more effective for patients presenting with melancholic depression at treatment baseline?
Conditions
- Depressive Disorder, Major
Interventions
Quetiapine 50 MG Extended Release Oral TabletDrug
OD
Quetiapine Fumarate XR 150-300 mgDrug
Dose ranged from 150 to 300mg, XR preparation, OD
PlacebosDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With 50 Percent Or Greater Reduction in the MADRS Score Over Time for the Quetiapine XR 150-300mg and Placebo 2 Arms/Groups Stratified by Depression Type (Melancholic vs. Nonmelancholic)Time frame: 1 - 6 weeks
- Modified MADRS Response RatesTime frame: 1 - 6 weeks
- MADRS Response RatesTime frame: Day 4 - Week 6
- Modified MADRS Response RateTime frame: Day 4 - Week 6
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.